Header

UZH-Logo

Maintenance Infos

Feline injection site sarcomas: data from Switzerland 2009-2014


Graf, R; Guscetti, Franco; Weller, M; Meier, D; Pospischil, A (2018). Feline injection site sarcomas: data from Switzerland 2009-2014. Journal of Comparative Pathology, 163:1-5.

Abstract

Feline injection site sarcomas (FISS) were first described in the early 1990s. Despite extensive research, the pathogenesis of these tumours has not been elucidated conclusively. Their appearance and the marked increase in their incidence has been mainly connected to the injection of vaccines, and it is assumed that a chronic inflammatory reaction at the injection site triggers subsequent malignant transformation. The role of alum-based adjuvants has been discussed, but is controversial. The present study of the Swiss Feline Cancer Registry (SFCR) with data from 2009 to 2014 revealed a marked decrease of the incidence of fibrosarcomas compared with the previous observation period. Notably, this drop occurred after a non-adjuvanted feline leukaemia virus vaccine was introduced in Switzerland in 2007. This observation, together with the previous findings of the SFCR, further supports the notion that alum-adjuvanted vaccines are involved in the genesis of FISS and that non-adjuvanted vaccines might be safer for cats.

Abstract

Feline injection site sarcomas (FISS) were first described in the early 1990s. Despite extensive research, the pathogenesis of these tumours has not been elucidated conclusively. Their appearance and the marked increase in their incidence has been mainly connected to the injection of vaccines, and it is assumed that a chronic inflammatory reaction at the injection site triggers subsequent malignant transformation. The role of alum-based adjuvants has been discussed, but is controversial. The present study of the Swiss Feline Cancer Registry (SFCR) with data from 2009 to 2014 revealed a marked decrease of the incidence of fibrosarcomas compared with the previous observation period. Notably, this drop occurred after a non-adjuvanted feline leukaemia virus vaccine was introduced in Switzerland in 2007. This observation, together with the previous findings of the SFCR, further supports the notion that alum-adjuvanted vaccines are involved in the genesis of FISS and that non-adjuvanted vaccines might be safer for cats.

Statistics

Citations

Altmetrics

Downloads

0 downloads since deposited on 10 Oct 2018
0 downloads since 12 months

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:05 Vetsuisse Faculty > Institute of Veterinary Pathology
Dewey Decimal Classification:570 Life sciences; biology
Uncontrolled Keywords:cat; feline leukaemia virus; fibrosarcoma; vaccine
Language:English
Date:August 2018
Deposited On:10 Oct 2018 10:24
Last Modified:10 Oct 2018 10:44
Publisher:Elsevier
ISSN:0021-9975
OA Status:Closed
Publisher DOI:https://doi.org/10.1016/j.jcpa.2018.06.008
PubMed ID:30213367

Download

Content: Published Version
Language: English
Filetype: PDF - Registered users only
Size: 644kB
View at publisher